A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Senti Biosciences
Affiliated Hospital to Academy of Military Medical Sciences
Celyad Oncology SA
Second Affiliated Hospital, School of Medicine, Zhejiang University
Thomas Jefferson University
GlaxoSmithKline
Hebei Senlang Biotechnology Inc., Ltd.
University of Michigan Rogel Cancer Center
University of Arkansas